

Index

- ABC transporters, 86, 136
acetylcholine, 50–51, 53, 58–59, 89, 94, 133, 314–316
acetylcholinesterase (AChE), 94, 133
action potential, 1, 57–58, 66–67, 83, 94, 103, 206–207
addiction, 45, 50, 60, 331, 333, 334, 337
Addison’s disease, 305, 306
adenohypophysis, 299
adenosine receptors, 124, 138
ADHD, 72, 73, 76–77, 188, 211–212, 214–215, 217–222, 254, *see* attention deficit hyperactivity disorder.
ADME, 85, *see* pharmacokinetics.
adrenocorticotrophic hormone (ACTH), 48, 136, 299, 303, 306
advanced phase sleep-wake phase disorder (ASWPD), 326
affinity, 90–92, 106, 114, 115, 137, 286
aggression, 34, 53, 304
agomelatine, 107–108, 109
agonists, 91–92, 106–108, 117–118, 136–139, 141–142, 342
agraphia, 7, 183
akinesia, 7, 44, 47
alcoholism, 24, 72, 74, 339
alexia, 7, 183
aliphatics, 111, 113
allelic variation, 230–231, 239, 240, 243, 255
allocortex, 14–16, 18
allostatic load, 304
alprazolam, 130
Alzheimer’s disease, 16, 134, 135, 171, 172, 181, 190, 255, *see also* dementia.
American Academy of Clinical Neuropsychology, 186, 196
American Academy of Sleep Medicine (AASM), 317–318
American Psychiatric Association (APA), 189, 195, 267, 331
amino acids, 127, 129, 139, 227, 228, 229, 232–233
amisulpride, 113, 115, 116
amitriptyline, 82, 100–102, 107
amnesia, 79, 82, 180, 290, 293, 327
AMPA, 59, 108, 134, 207
 receptors, 59, 134, 207
amphetamines, 82, 96, 98, 120, 138–139, 140, 141
amygdala, 5–6, 26, 27, 36, 37, 38, 39, 40, 52–53, 169, 170, 314–315, 342–343
 abnormalities, 40
 anatomy, 26, 30–32, 35–39
 autism spectrum disorder and, 217
 extended, 36–39, 42
 function, 15, 36, 53, 208, 341
 imaging, 169
 links, 19, 20, 23, 35, 36, 40–41
 plasticity, 40
 threat response, 39, 73
Angelman’s syndrome, 253
anosmia, 25
antagonists, 91–92, 106, 108, 114, 115, 137, 336
anterior cingulate cortex (ACC), 18–20, 164, 167, 168, 169–170, 338, 340
anterior insula, 14, 16, 20, 23, 30, 36, 336
antibodies, 284–285, 287, 289–290, 291, 293, 294, 296–297
antibody-secreting cells (ASC), 284, 287–288
anticholinergics, 83, *see* antimuscarinics.
anticonvulsants, 113, 123, 296, 329
antidepressants, 102, 105–110, 113–114, 328
antiepileptics, 109, 120, 123–124, 142
antimuscarinics, 83, 118–120
antipsychotics, 109–118, 119, 120, 295–296, 329
 atypical, 110
anxiety disorders, 46, 52, 190–193, 292–294, 305–306, 324, 327–328
 generalised, 48, 73
apathy, 19–21, 32, 35, 80, 82, 185, 306
aphasic syndromes, 182
apparent diffusion coefficient (ADC), 153
aripiprazole, 110–111, 113–114, 116
arterial spin labelling (ASL), 153, 154–156
ascending reticular activating system (ARAS), 12, 314–330
asenapine, 111, 114, 116
Asperger’s syndrome, 33, 175, 214
atomoxetine, 108, 222
attachment, 14, 208, 210
attention, 179–181
attentional bias, 169–170, 331
attention deficit hyperactivity disorder (ADHD), 32
 adult-onset, 220
 in children, 83, 221–222
 diagnosis, 77, 160, 212, 219
 neurological basis, 32
 symptoms, 219–220, 221
 treatment, 108, 140
auditory-visual association cortex, 7
autism spectrum disorder, 40, 76–77, 164, 165, 212, 213, 214, 216, 217, 218, 254, 279, 280
 comorbidities, 72, 77, 220, 249, 326
 epilepsy, 77
 computational view, 279–280
 definition, 33
 genetic factors, 206, 253–254, 257, 304
 neuroanatomy
 amygdala, 39–40
 neurodevelopmental model, 212–222
 neuroimaging studies, 164–165
 theory of mind, 162–164
autoantibodies, 283, 285, 288–289, 292
autoantibody-mediated autoimmune disease, 288, 289
autoimmune encephalitis, 289–292, 296
axons, 1, 4, 5, 11, 56, 66–67, 203–205
azathioprine, 296
BADS, 186, *see* behavioural assessment of the dysexecutive syndrome.
barbiturates, 117, 126–129
bariatric surgery, 332, 337, 340–341, 342
barriers, blood brain, 4, 85, 152, 158, 292
basal forebrain (BF), 36, 50, 53, 315–316, 320

Index

- basal ganglia, 3, 5, 18, 42–45, 47, 167–169, 313–315
- basal nuclei, 5, 36, 54
- Bayesian brain hypothesis, 271, 274, 275, 277, 281
- BBB, 85, *see* blood-brain barrier.
- B-cell receptors (BCR), 284, 286
- BDNF, 90, 109, 122, 205, 206, 207, 211, *see* brain-derived neurotrophic factor.
- BDZ, 74, *see* benzodiazepines.
- behavioural assessment of the
 dysexecutive syndrome, 186
- benzamides, 97, 111, 113, 115–116
- benzisoxazoles, 111, 113
- benzodiazepines (BDZ), 74, 82, 87, 100, 126–130, 132–133, 136
- Bereitschafts potential, 70
- binding affinity, 90–91, 97
- binge eating, 335–336, 337, 340, 343
- bioavailability, 106, 108–109, 116, 119, 130–132, 134–135, 137–138
- biomedicine, 263
- biopsychosocial models, 260, 264, 268–269, 270, 271, 281, 294
- bipolar disorder, 120, 167–169, 256, 257–258, 321–322, 324, 326
- blood–brain barrier, 85, 87, 115, 116, 119–120, 134–135, 139
- blood oxygen level dependent (BOLD)
 signalling, 154–156, 162, 338, 339, 341, 342
- BMI, 334, *see* body mass index.
- B-mitten wave, 71
- BMPs, 199, 202, *see* bone morphogenetic proteins.
- body clock, 326
- body mass index (BMI), 334–335, 336, 337–338, 339, 340, 342
- bone morphogenetic proteins (BMPs), 199, 202
- borderline personality disorder (BPD), 53, 221, 258
- bovine spongiform encephalopathy (BSE), 256
- BPAD, 73, *see* bipolar disorder.
- brain-derived neurotrophic factor (BDNF), 90
- brain injury, 194, 205, 212
- brain plasticity, 109, 154, 171
- brain stem, 4–5, 7–14, 50–51, 53, 315–316, 320
- butyropheneone, 82, 111, 113
- Ca-calmodulin-dependent protein kinase II, 134
- caffeine, 123, 138
- CaMKII, 134, *see* Ca-calmodulin-dependent protein kinase II.
- cannabidiol (CBD), 141–142
- cannabis, 35, 45, 141, 142, 181
- carbamazepine, 79, 113, 123, 124, 125, 258, 305
- cardiovascular disease, 123, 190, 210, 268, 304, 310, 331
- cariprazine, 110–111, 114
- cataplexy, 304, 325
- catecholamines, 51, 94, 307
- catechol-O-methyl-transferase, 94
- caudate nucleus, 36–38, 39, 42–46, 338, 339–340, 341, 342–343
- CBD, 141–142, *see* cannabidiol.
- CBT, 46, 222, 264, 328, *see* cognitive-behavioural therapy.
- central nervous system (CNS), 1, 261, 263, 268, 269, 312–315
- central sleep apnoea (CSA), 329
- central sulcus, 4, 28
- cerebellar motor syndrome, 13
- cerebellum, 3–5, 11–13, 40, 313, 315
- cerebral cortex, 1–3, 4, 6–7, 16–18, 48–49, 53–54, 313–315
- cerebral hemispheres, 4–10, 11, 27, 28, 37
- cerebral lesions, focal, 72, 80, 84
- cerebro-spinal fluid, 1, 5, 21, 152, 153, 309, 325
- children, 77, 160–161, 165, 187–188, 211–212, 216–221, 242–243
- chlorpromazine, 87, 100–101, 111, 115, 116, 117
- chromosomes, 224–227, 230–237, 238, 239–240, 242–243, 252
 definition, 224–225
- cingulate cortex
 anterior, 18–19, 20, 32, 83, 168, 169, 170
 posterior, 18–54
- cingulate gyrus, 15, 17–18, 20–21, 23–24, 30, 34, 40–41
- circadian rhythm disorders, 322, 327
- citalopram, 103–105
- claustrum, 5, 27–28, 30, 314
- clonidine, 222
- clozapine, 82, 110–111, 113, 114–118, 167
- CMAP, 66, *see* compound muscle action potential.
- CNS, 1, *see* central nervous system.
- cocaine, 50, 119, 140, 141, 334
- cognitive assessment, 174, 191
 attention and memory, 181
 executive function, 189
 intellectual functioning and deterioration, 175
 language, 185
 perceptual and visuospatial functioning, 183–185
 premorbid function, 179
- cognitive-behavioural therapy (CBT), 46, 222, 264, 328
- cognitive enhancers, 94, 133, 135
- cognitive impairment, 187, 190, 292–293, 310, 312, 328, 329
- cognitive psychology, 175
- compound muscle action potential (CMAP), 66–69
- computed tomography (CT), 149–151, 158
- COMT, 94–145, 233, 339, *see* catechol-O-methyl-transferase.
- concentration gradients, 57–58, 122, 140, 201–202
- contingent negative variation, 70
- corpus callosum, 4, 6–10, 14, 16–17, 19, 20, 24
- corpus striatum, 4–5, 6, 42–43
- cortex, cerebellar, 12, 13
- cortical excitability, 12, 54, 70, 83
- cortical thickness, 149, 152, 167, 171, 221
- cortisol, 48, 301–304, 306
- cranial nerves, 1–2, 3
- Creutzfeldt–Jacob disease (CJD), 256
- CT, *see* computed tomography.
- Cushing's syndrome, 305, 306
- cytochrome P450, 87, 144
- cytogenetic testing, 246
- daughter chromosomes, 233–235
- DBS, 20, *see* deep brain stimulation.
- deep brain stimulation (DBS), 20, 44, 54, 55, 83, 154, 166
- default mode network (DMN), 35, 155, 164, 168, 222
- delayed sleep–wake phase disorder, 324, 326
- deletion syndrome, 253, 257
- delirium, 63, 74, 77, 82, 119, 189, 306–307
- Delis–Kaplan executive function scale, 186
- dementia
 assessments, 175
 frontotemporal, 25, 34, 74, 77, 255
 genetic risk factors, 254
 Lewy body (DLB), 16, 135
 mixed, 135
 moderate, 54
 subcortical, 16, 256
 vascular, 16, 135, 256, *see also* Alzheimer's disease.
- dentate gyrus, 4, 21–22, 210
- depression, 50, 190–194, 257–258, 292–294, 295, 320–324
 major depressive disorder (MDD), 48–49, 73, 83, 168, 189, 321, 326
- diazepam, 102, 126, 129–130, 132

- dibenzo-oxepinopyrrole, 111
diencephalon, 4–7, 12, 44, 47, 53
diffusion tensor imaging (DTI), 148, 152, 333
diphenylbutylpiperidines, 111, 113
disability, 254, 267–268, 292
DIVE disease model, 171
DLB, 16, *see* dementia, Lewy body.
DNA, 224–228, 229, 232, 233–234, 240–242, 245
 daughter chromosomes, 233–235
 methylation, 209, 228, 245, 250–251
 mitochondrial, 225, 236
 splicing, 227, 228, 229, 232–233
 transcription, 227–228, 229
donepezil, 133, 134–135
dopamine, 44, 45, 50–51, 58–59, 94, 313–314, 336
dopamine, neural pathways, 333, 334, 335–336, 339
dopamine receptors, 44, 138, 339
dorsal raphe, 313–315
dorsal striatum, 43–44, 52, 335, 337, 339
Down's syndrome, 252, 255
drug addiction, 331, 333, 334, 335, 337–338
drug–drug interactions, 100, 117, 137–138, 144
DSM-5, 75, 189, 214–216, 219, 267, 269, 337
DSWPD, *see* delayed sleep–wake phase disorder.
duloxetine, 105–106
dyslamine, 16

eating, 99, 216, 337–338, 339, 340, 341
Edwards{,} Roy, 147
egg cells, 234
electroencephalography (EEG)
 background, 63, 72–73, 74, 82
 brain rhythms, 63
 intracranial recordings, 71
electroencephalography (EEG), 60–61, 64–66, 71–72, 74, 77–81, 148–149, 159–161
electromyography, 66, 67, 73, 319
electrooculograms, 312–319
electrophysiological recordings, 55–56
embodied cognition, 261, 262, 264
emotional eating, 337–338, 339, 340
encephalitis, 60, 71–72, 80–81, 123, 289, 293, 296
encephalopathy, 71–72, 74, 77, 293
endocannabinoid system, 141
endocrine cells, 298, 301
endocrine disorders, common, 305, 306
endocrine systems, 7, 298–299, 307
entorhinal cortex, 15, 16, 18, 20–24

ependymal cells, 4
epilepsy, 63, 71–72, 74–75, 77, 78–79, 82–84
epileptiform discharges, 72, 74, 77, 78, 82–83
epinephrine, 301–302
episodic memory, 18, 20, 24, 25, 40, 48, 180–181
escitalopram, 103–105
esketamine, 108–109
event-related potential (ERPs), 69, 83
evoked potentials, 55, 69–70, 73, 81
executive function, 32, 48, 69, 77, 185–189
exomes, 225–226
eye tracking dysfunction (ETD), 276

FDCs, 286–287, *see* follicular dendritic cells.
fluoxetine, 103–105, 135, 206
flupentixol, 83, 111, 115
follicle stimulating hormone, 298
follicular dendritic cells (FDCs), 286–287
food addiction, 331, 335, 337
forensic neuropsychology, 191
fornix, 7, 15, 20–24, 38, 42
fractional anisotropy, 153, 154, 171, 335
fragile X syndrome, 252, 254, 255
FSH, 298–299, *see* follicle stimulating hormone.
functional MRI (fMRI), 151–154, 162, 169–170, 332, 333, 340
fusiform face area (FFA), 7, 164, 213, 217
fusiform gyrus, 7, 217

GABA (γ-amino butyric acid), 3, 58–59, 94, 98, 127–129, 157, 315–317
Gaucher disease, 253
gene expression, 201, 210, 226–229, 233, 245, 250–251
 translation, 227, 228–229
general adaptation syndrome (GAS), 302
genetic risk scores, 249
genetic variation, 230–232, 238, 239, 245–246, 247, 251, 257–258
genomes, 225–226, 230–231, 236–237, 240–242, 244, 245
genome-wide associations studies, 244
genotype, 108, 229–230, 238–239, 240, 243, 244–245
germinal centres (GC), 286–287
GHB (γ-hydroxybutyrate), 115
glial cells, 1, 4, 199
globus pallidus, 5, 10, 42–43, 313–314, 315, 339, 341

glucocorticoids, 210, 301, 302, 303
glutamate, 51, 58–59, 127, 156–157, 165, 167, 315–317
glutamatergic neurons, 313–314, 316
glycogen synthase kinase-3, 121–122
G-protein-activated inwardly rectifying K (GIRK) channel, 103, 136
G-protein-coupled receptors (GPCR), 55, 89–91, 127, 129, 141, 303
granule cells, 1–3, 12
grey matter, 1, 4–5, 28, 149–152, 153, 160
growth hormone, 299, 302, 303, 306
GSK3, 121–122, *see* glycogen synthase kinase-3.
guanfacine, 222
GWAS, 244, 247–249, 256, 257–258, 261, *see* genome-wide association studies.

hallucinations, 21, 30, 165–166, 276–277, 305–306, 325
haloperidol, 83, 86, 111, 113, 115, 116
hemodynamic response function (HRF), 332
heritability, 220, 247, 249, 257, 339
hindbrain, 53, 199, 201–202
hippocampal allocortex, 15, 21–23
hippocampus, 3–26, 40–42, 52–54, 210–211, 314–315
HLA, 126, 258, 284, 325, *see* human leucocyte antigen.
homeostasis, 48, 298, 302, 304, 319–320, 333–334, 336
hormonal interactions, 302
hormones, 88–90, 210–211, 298–304, 307, 315, 318, 342–343
HPA, 48, 172, 210–211, 303, 304, 306, *see* hypothalamic–pituitary–adrenal axis.
HPG, 304, *see* hypothalamus–pituitary–gonadal axis.
human leucocyte antigen, 126
Huntington's disease, 44, 178, 224, 244, 250, 254
hyperactivity/impulsivity, 219, 220, 221
hypercholesterolemia, 256
hypersomnia, 82, 295, 321–322, 324, 326
hypersomnolence, 305, 324, 326
hyperthyroidism, 305
hypothalamus, 6–10, 36, 37–38, 47–54, 299–300, 314–316
 lateral, 7, 50, 141, 314–317
hypothalamus–pituitary–adrenal (HPA) axis, 48
hypothalamus–pituitary–gonadal (HPG) axis, 304
hypoxia, 213, 318

Index

- IEDs, 63, 78–80, 82, *see* interictal epileptiform discharges.
 IL-6, 295–296, *see* interleukin-6.
 imaging, CT scanning, 149–151, 158
 imipramine, 100, 102, 124
 immunotherapies, 283, 290–292, 294, 297
 immunotherapy, 290–293, 294
 impulsivity, 32, 34, 53, 219–220, 222, 338, 340
 inferior frontal gyrus (IFG), 7, 32, 34, 164, 169, 170, 338
 inflammation, 283, 287, 289, 294, 295, 303, 305
 inflammatory diseases, 283, 294
 systemic, 294
 inhibitory control, 211, 338, 341
 insomnia, 291, 293, 318–324, 326–327, 329
 insula, 26, 27–30, 42, 164, 336, 338–341
 insular cortex, 28, 314
 insulin, 90, 301, 333, 341
 intellectual disability, 212, 217, 221, 249–254, 257, 258
 interictal epileptiform discharges, 63
 interleukin-6, 295–296
 International Classification of Diseases (ICD), 267, 269
 International Classification of Sleep Disorders, 323
 International League Against Epilepsy (ILAE), 75
 interneurons, 3, 54, 61, 77, 88, 290
 intravenous immunoglobulin, 296
 ion channels, 55, 56–59, 88–89, 101, 103, 141–142
 IQ, 33, 171, 175, 178
 irregular sleep–wake rhythm disorder, 327
 IVIG, 296, *see* intravenous immunoglobulin.
 kainic acid receptors, 89
 ketamine, 108–109, 134
 Kleine–Levin syndrome (KLS), 81, 324, 326
 Klüver–Bucy syndrome, 6, 15
 lamotrigine, 79, 123, 125, 126
 language, 6, 182–185, 211
 lateral sulcus, 4, 26, 27–29
 lentiform nuclei, 5, 6, 42–43, 54, 341
 leptin, 302, 303, 333, 341–342
 lesions, 28–29, 48, 79, 182, 183–186, 316
 leucine-rich glioma inactivated 1 protein (LGI1), 289–290, 292–293
 LH, 298–299, 316, *see* luteinizing hormone.
 liability-threshold models, 246–247
 light microscopy, 16, 231, 239, 252
 limbic encephalitis, 289, 292
 limbic lobe, 4, 14–18, 20, 26–27, 52, 53
 limbic loop, 45, 47
 limbic system, 14–15, 18, 168, 313
 linkage, 234, 242, 243, 244, 246, 263
 lipid–water partition coefficient, 87
 lipophilicity, 87, 116, 129–130
 lithium, 82, 87, 120–123, 124, 125–126, 305, 329
 locus coeruleus, 11, 50, 52, 54, 169, 313–316
 lod scores, 246
 logistic regression, 247
 long-term depression, 11
 long-term memory (LTM), 180
 long-term potentiation, 59
 lorazepam, 100, 118, 129–130, 132
 loxapine, 111, 113
 LTD, 11, 59, 207, *see* long-term depression.
 LTM, 180, *see* long-term memory.
 LTP, 59, 134, 206–207, 208, 211, *see* long-term potentiation.
 lupus, 292–294
 luteinizing hormone (LH), 298
 machine learning, 168, 172
 magnetic resonance imaging (MRI), 147–152, 158, 160–161, 171, 332
 magnetic resonance imaging (MRI) functional (fMRI), 154, 162, 331–332, 333, 340
 magnetic resonance imaging (MRI), structural (s-MRI), 149, 152, 160–162, 168
 magnetic resonance spectroscopy (MRS), 156–158, 161, 168, 171
 magnetoencephalography (MEG), 60, 65–66, 148, 159–161, 169
 major depressive disorder, 48
 MAOIs, 82, *see* monoamine oxidase inhibitors.
 marker alleles, 242, 243
 maternal immune activation (MIA), 294
 MCH, 315, 317, *see* melanin-concentrating hormone.
 MDD, 48–49, 73, 83, 168, 189, 321, 326, *see* major depressive disorder.
 MDMA, 139, 141
 medulla oblongata, 9, 11
 melanin-concentrating hormone (MCH), 315, 317
 melanocyte-stimulating hormone (MSH), 299
 memantine, 133, 134, 135
 memory
 flashbulb, 40
 implicit, 25, 180
 long-term, 25, 180
 short-term, 25, 180
 Mendelian diseases, 238, 242, 250
 mesocortex, 14–16, 22
 metabolism, 87, 98, 104–107, 124, 130–131, 136–137
 methadone, 102, 137, 138
 methylphenidate, 140, 141, 222, 326
 microglia, 4, 292, 294–295
 midbrain, 9–12, 43–44, 52–53, 54, 335, 338, 339
 midcingulate cortex, 1–20
 mild cognitive impairment (MCI), 26, 170–171, 175, 181, 190–193
 mirtazapine, 107, 329
 misdiagnosis, 82, 178, 184, 195, 212, 290
 mismatch negativity, 69–70, 73
 mitochondria, 95, 129, 142, 225, 230, 234–236
 mitosis, 233–237
 moclobemide, 97, 98
 modafinil, 140–141, 326
 model systems, 245
 monoamine oxidase inhibitors, 82, 96–97, 98, 100, 101
 monoamine oxidases (MAO), 95
 mood stabilisers, 120, 124, 125, 296
 morphine, 135–137, 138, 337
 MORs, 136–137, 333, 336, 337, *see* Mu opioid receptors.
 motor cortex, 3, 56
 primary, 3, 7, 15, 16, 20, 45
 motor unit action potential (MUAPs), 67
 MRI, 6, *see* magnetic resonance imaging.
 MS, 73, 75, 189, 190, 292–294, 297, *see* multiple sclerosis.
 MSLT, 65, 325, *see* multiple sleep latency test.
 MUAPs, 67, *see* motor unit action potential.
 multiple sclerosis (MS), 73
 multiple sleep latency test (MSLT), 65
 Mu opioid receptors, 136
 muscarinic sites, 116, 118
 myasthenia gravis, 288–289
 mycophenolate mofetil, 296
 myocardial infarction (MI), 247
 myopathy, 68
 naloxone, 137–138
 naltrexone, 137–138, 337

- narcolepsy, 54, 64–65, 321, 322, 324, 325, 328
- National Adult Reading Test (NART), 178
- near infrared spectroscopy (NIRS), 157
- neocortex, 14–16, 18, 25, 53, 198, 210
- nerve conduction studies (NCS), 55, 66–67, 73, 75
- nerve growth factor (NGF), 90, 210
- nervous system, 1, 55, 58, 202, 260, 298
- neurodevelopment, 198, 206, 210, 211, 212, 214
- abnormal, 212–222
- attachment, 208–210
- maps and circuits, 204–206
- neural induction, 199
- neuroectoderm patterning, 201–202
- neurogenesis and neural migration, 202–204
- neuroplasticity, 206–208
- neurulation, 199
- neurodevelopmental disorders, 76, 202–203, 206, 212–213, 214, 221, 222
- neurogenesis, 3–4, 40, 103, 202, 204
- neuroimaging, 148–149, 169, 171, 172, 173, 332, 333
- applications, 160
- neuroleptic drugs, 82, 99–100, 117, 291
- neuroligins, 254
- neurological disorders, functional, 73, 75, 191, 281
- neuromodulators, 36, 50–52, 88, 273, 277
- neuromuscular junction, 3, 67
- neuronal activity, 78, 153, 158, 161, 162, 245–246, 333
- neurons, 1–4, 21–24, 48, 56–60, 88, 316–317
- neuropathy, 68
- neuropeptides, 54, 103, 302, 303–304
- neurophysiological tests, 55–56, 72, 84
- neuroplasticity, 206–207, 208, 211
- neuropsychological assessment, 77, 174, 175, 189–191, 196
- neuropsychological assessment, diagnostic issues, 191
- neuropsychological assessment battery executive module, 186
- neurotransmission, 4, 88, 92, 276
- neurotransmitters, 3, 51, 58–59, 88–90, 92, 302, 303
- neurulation, 198–199
- NGF, 90, 210, *see* nerve growth factor.
- nightmare disorder, 328
- NMDA (N-methyl D-aspartate), 59, 125, 134, 207, 283, 290
- receptor, 59, 134, 137, 207, 283, 290, 291–293
- non-rapid eye movement, 328, *see* NREM.
- non-steroidal anti-inflammatory drugs, 105, 123, 296
- noradrenaline, 7, 11–12, 50–52, 58–59, 98, 313–316
- NSAIDs, 105, *see* non-steroidal anti-inflammatory drugs.
- nucleus accumbens, 45–46, 331, 334, 335–337, 339–342
- obesity, 247, 251, 331, 332, 333–342, 343
- obsessive-compulsive disorder (OCD), 19, 39, 45–46, 48, 73, 83
- obstructive sleep apnoea, 324, *see* OSA.
- OCD, 19, *see* obsessive-compulsive disorder.
- oestrogens, 302–303, 318
- olanzapine, 86, 111, 113, 115, 296, 329
- olfactory bulb, 3, 4, 26, 50, 52, 53, 314
- olfactory cortex, 26–27
- primary, 26–27
- olfactory nerves, 3, 26
- olfactory tract, 23, 26–27, 36
- opioid receptors, 135–136, 336
- opioids, 59, 100, 132, 135–136, 138, 323, 334
- orbital cortex, 32, 33, 34
- lateral, 34, 46
- orbitofrontal cortex, 32, 33, 35, 45, 167–168, 169, 172
- orexin, 50, 53–54, 103, 140–141, 314, 316–317, 341
- orthosteric site, 92
- ovarian teratomas, 290, 293
- oxytocin, 42, 88, 103, 300–301, 304
- pallidum, 43–44, 338, 341
- PAMPs, 283–284, *see* pathogen-associated molecular patterns.
- panic attacks, 39, 73–74, 307
- panic disorder, 48, 73, 324
- paradoxical kinesis, 47
- parahippocampal gyrus, 16–18, 20–23, 169, 188, 338
- paranoia, 165, 278
- parasomnias, 64, 322, 324, 327–328
- parathyroid hormone, 300–302
- Parkinson's disease, 16, 44, 45–47, 96, 97–98, 190
- paroxetine, 103–105, 135
- pathogen-associated molecular patterns, 283–284
- pattern recognition receptors (PRR), 283–284
- PCR, 240, *see* polymerase chain reaction.
- performance validity tests, 187–188
- periamygdaloid cortex, 26–27, 36
- periodic limb movement disorder, 321, 324–329
- peripheral nervous system (PNS), 1, 289
- personality disorders, 40, 72, 74, 188, 256, 257, 326
- PET, 114, 148, 158–159, 170, 171, 333, 335, *see* positron emission tomography.
- pharmacokinetics, 85–86, 97, 98, 103, 119, 122, 124–125
- phenelzine, 97, 98
- phenethylamine, 96, 138
- phenothiazines, 82, 110–113, 115
- pimozide, 111, 116
- pineal gland, 42, 47, 49, 108, 299–300
- piperidines, 111–113, 133
- piriform cortex, 26–28, 34
- piriform lobe, 26, 41
- pituitary gland, 52, 299, 303
- PKC, 121, 139, *see* protein kinase C.
- PLMD, *see* periodic limb movement disorder.
- PNS, 1, 289, *see* peripheral nervous system.
- polymerase chain reaction, 240–241, 244
- positron emission tomography, 114
- posterior cingulate cortex (PCC), 18, 20, 35
- posterior dominant rhythm, 62–63, 65–66, 74, 78
- posterior hippocampus, 24, 25
- posterior insula, 28–29
- posterior lateral fusiform (PLF), 172
- post-traumatic stress disorder (PTSD), 40
- potassium, 57–58, 122
- Prader–Willi syndrome, 253, 339
- predictive coding, 271, 281
- pregabalin, 131
- premorbid function, 177–179
- premotor potentials, 69
- prion disease, 256
- proton density (PD) MRI, 149, 332
- psychogenic non-epileptic seizures, 72, 74–76
- psychology, 148, 260–261, 262, 264, 268
- psychoneuroendocrinology, 303, 307
- psychosis, 79–80, 165, 166–167, 275–279, 290–294, 295
- acute, 119, 295
- chronic, 165
- mood disorders, 290, 296
- peri-ictal, 71–72
- psychotic disorders, 26, 71, 188, 190, 291

Index

- PTH, 300–302, *see* parathyroid hormone.
- PTSD, 40, 50, 52, 169–170, 323, 327, 328, *see* post-traumatic stress disorder.
- putamen, 5, 42–44, 168, 334–335, 338, 339–343
- PVTs, *see* performance validity tests.
- pyramidal cells, 3, 60–61, 159, 273
 superficial, 273, 275, 276
- pyramidal neurons, 14–15
- quetiapine, 111, 113, 115, 116
- quinolinone, 111
- rabies, 15
- rapid eye movement (REM) sleep, 25, 65, 311, 315, 316–319
- rapid eye movement, 25, *see* REM.
- Ravens Standard Progressive Matrices II, 175
- RBD, 318–322, 328, 329, *see* REM behaviour disorder.
- RBS (response bias scale), 188
- RDoC, 264–267, 281, *see* research domains.
- reactivity, 63, 286
- readiness potential, 70
- reboxetine, 108
- receptors, 58–59, 88–94, 107–108, 113–114, 115, 127–129, 302–303
 α -adrenergic, 107
 AMPA, 59, 134, 207
 androgen, 232
 β -adrenergic, 97
 B-cell, 284, 286
 cannabinoid, 142
 cholinergic, 102, 118
 dopamine, 44, 138, 339
 ghrelin, 341
 glucocorticoid, 303
 G-protein-coupled, 59, 89–91, 127, 129, 141, 303
 kinase-dependent, 303
 metabotropic, 58, 89, 125
 mineralocorticoid, 210
 nicotinic acetylcholine, 58
 NMDA, 134, 273, 290
 opioid, 135–137, 333, 336, 337
 oxytocin, 139
 purinogenic, 89
 raphe, 107
 serotonergic, 100, 106
 striatal D2, 114, 335
 tyrosine kinase, 90, 121
 vasopressin, 113, 304
- recombination, 234
- reference genome, 230–231, 245
- REM (rapid eye movement) sleep, 64–65, 72–73, 312–315, 317–329
- REM behaviour disorder, 318
- research domains, 264
- respiratory depression, 103, 136–137, 138
- response bias scale (RBS), 188
- response inhibition, 221
- resting membrane potentials, 57–58, 134
- restless legs syndrome, 321–324, 328–329
- reticular formation, 8–12, 63, 314–315
- reward system, 338, 343
- Reynolds intellectual assessment scales II, 175
- rheumatoid arthritis, 287, 294, 297, 303
- risperidone, 86, 100, 111, 113
- rituximab, 296
- rivastigmine, 133, 134–135
- RNA, 224, 226–229, 245
- RNA genes, 228–229
- RNA polymerase, 227
- Sanger sequencing, 244–245
- schizophrenia, 20, 30, 167, 213, 214, 256–258, 276–277
 aggression, 53
 associated brain dysfunction, 28–30, 48, 52, 71, 160, 199
 childhood onset, 161
 cingulate gyrus and, 21, 26
 cognitive tests, 175, 178
 comorbidities, 111, 178
 differential diagnosis, 189
 double bookkeeping, 278
 electroencephalography (EEG), 72
 etiology, 114
 genetic factors, 172, 206, 249–250, 257
 mechanisms underlying, 109
 neuroanatomy, 30, 34
 neurodevelopmental model, 212, 213–223
 neuroimaging, 161
 psychopathology, 276
 symptoms, 165–167, 277, 290–291, 294
 treatment, 110, 116, 119, 296
 treatment resistance, 167
- Schwann cells, 4, 199
- sedative/hypnotics, 126, 129, 131–132, 138
- seizures
 epileptic, 74–75, 78, 80
 psychogenic non-epileptic (PNES), 75
- temporal lobe, 74
- selectivity, 92, 97, 101, 115, 119, 158
- selegiline, 97–98
- septum, 41–42, 44, 50, 308–315
- serotonin, 7, 50–52, 53, 94–97, 313–316
- serotonin-selective reuptake inhibitors (SSRI), 46, 101, 103–106, 109–110, 326, 328, 329
- serotonin syndrome, 99, 101
- SERT, 94–95, 101, 103, 105–106, 108, 137, 138
- sertindole, 111, 117
- sertraline, 103–105
- short-term memory (STM), 25, 180, 188, 306
- single nucleotide polymorphisms, 144, *see* SNPs.
- single photon emission computed tomography (SPECT), 114, 158, 170
- sleep, 53, 308–329, 330
 ageing and, 318–319
 definition, 308
 disorders, 323–329
 electroencephalography (EEG), 63–65, 74, 78
 fMRI, 162
 function, 308–311
 hypersomnia, 82
 medications affecting, 329–330
 neurobiology, 312
 non-rapid eye movement (NREM), 64, 72–73, 310, 312–315, 317–319, 320
 psychiatric disorders and, 320–323
 regulation, 7, 319–320
 structure, 312–318
 deep sleep, 310, 312, 316–318, 319, 323, 327–328, 329
 light sleep, 316–318
 rapid eye movement (REM), 25, 317
 sleep apnoea, 318, 320–329
 sleep disorders, 318, 320–321, 322, 323, 326, 329, 330
 sleepiness, 310, 326, 328
 sleep regulation, 7, 319, 320
 sleep rhythms, circadian, 320
 sleep spindles, 64–67, 132, 316
 sleep stages, 65, 74, 312–318, 319, 327
 sleep studies, 64–65
 SLOs (secondary lymphoid organs), 286
 slow wave sleep, 310, *see* SWS.
- SNPs (single nucleotide polymorphisms), 144, 167, 240–242, 244, 247, 248–250
- social cognition, 18, 33, 77, 164–165, 185, 189
- sodium, 57–58, 123, 126

- solute carrier (SLC) transporters, 86
sperm cells, 234
SSRIs, *see* serotonin-selective reuptake inhibitors.
strange situation test, 209
stress responses, 50, 305, 338
stroke, 13, 20, 48, 81, 189, 191, 256
 dementia following, 48
 paralysis, 20
structural MRI (sMRI), 4, 8–11, 13–14, 53, 149, 160–162, 313–315
substance abuse, 190, 191, 220, 304, 322, 331, 337
substantia nigra, 9–10, 43–44, 52, 167, 273, 342, 343
suicidal ideation, 168, 321
suicidality, 109, 167–168
suicide, 49, 167–168, 304, 321, 328
sulpiride, 111, 113, 115, 116
surface based morphometry, 152
sylvian fissure, 4, *see* lateral sulcus.
symptom validity tests, 187, 188
synapses, 3, 59, 88–89, 94, 205, 257, 311
synaptic plasticity, 42, 54, 59, 90, 208, 311
synaptic potentials, 57, 58
synaptogenesis, 205, 211, 216

Tay–Sachs disease, 253
TCAs, 82, *see* tricyclic antidepressants.
telomeres, 224, 227, 231, 234
temporal lobe epilepsy, 4
temporal lobes, 5, 6, 25–27, 35–37, 77, 79, 289
testosterone, 206, 232, 298, 299, 302–303, 304
tetrabenazine, 110

thalamic nuclei, 47–48, 204
thalamus, 6–7, 27–28, 43–44, 47–48, 53–54, 168–169, 313–315
theory of mind (ToM), 33, 162–164, 217
thienobenzodiazepine, 111, 113
thioxanthenes, 111, 113
thyroid hormones, 90, 299, 302–303, 305
thyroid-stimulating hormone, 299
TLE, 4, 72–76, *see* temporal lobe epilepsy.
ToM, 33, *see* theory of mind.
total sleep time, 65, 72, 323, 325, 329
tramadol, 137, 138
tranylcypromine, 96–97, 98
trauma, 150, 165, 169–170, 183, 191, 327
trazodone, 106–107, 329
treatment-resistant depression, 109
treatment-resistant schizophrenia, 167
tremor, 73, 75, 83, 159, 281
tricyclic antidepressants, 82, 100–103, 105, 106, 109, 110, 329
trifluoperazine, 111
trinucleotide, 231, 252, 255
TRS, 167, *see* treatment-resistant schizophrenia.
TSH, 299, *see* thyroid-stimulating hormone.
tyramine, 96, 97, 99

Urbach–Wiethe disease, 39

vagus nerve stimulation, 55
valproate, 123, 125–126
valproic acid, 123–124

vasopressin, 304
venlafaxine, 105–106, 109
ventral tegmental area, 44, 52, 313–314, 315, 335–336, 340, 341–342
ventricular zone, 4, 202–203
VGKC, 289–290, 291
visual cortex, primary, 3, 7, 15, 16, 59, 205, 273
VNS, 55, 83, *see* vagus nerve stimulation.
vortioxetine, 106
voxel-based morphometry (VBM), 152–153, 333, 334–335
voxel imaging, 151–153, 155–156, 332, 333, 335

Wada testing, 6
Wechsler adult intelligence scale (WAIS), 175–176, 177, 178, 196
weight loss, 305, 338, 340–343
Wernicke’s area, 7, 182, 277
white matter, 5–10, 12, 14, 30–31, 42–43, 149–153, 335
Williams syndrome, 213
WMT, 187, *see* word memory test.
word memory test (WMT), 187–188
working memory, 25, 32–33, 44, 45, 169, 175–176
World Health Organization (WHO), 215, 267
 Disability Assessment Schedule (WHODAS), 267

zaleplon, 127, 130–131
zolpidem, 127, 130–131, 132
zopiclone, 127, 130–131, 132, 322